Rapalink-1, a rapamycin-based drug, extends yeast lifespan in lab study
A study from Queen Mary University of London, carried out in yeast, found that Rapalink-1 extended lifespan in a way similar to rapamycin. The results are early and show no evidence of benefit in people.
Source: Rapalink-1, a rapamycin-based drug, extends yeast lifespan in study (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The study, led by researchers at Queen Mary University of London, used yeast as its experimental model. In it, Rapalink-1, a rapamycin-based drug, extended the lifespan of yeast in a way similar to rapamycin itself. Molecular analyses linked this effect, in part, to enzymes that convert agmatine, a compound produced by gut bacteria.
These are early laboratory findings about pathways linked to aging, not tests in people. Yeast is a simple organism that is useful for studying basic aging processes, but what happens in yeast does not always happen in humans. So far there is no evidence of benefit for human health.
What it means
The result suggests that a cell pathway linked to rapamycin and aging may be studied through new routes, including the action of compounds made by gut bacteria. It is not yet known whether this effect occurs in animals or people, or whether it would be safe or useful.
How to read it with care
This finding does not replace a medical consultation. Anyone considering a change in diet, supplements or any treatment should talk to a doctor or another qualified health professional.